Hoth Therapeutics, Inc. – NASDAQ:HOTH

Hoth Therapeutics stock price today

$1.27
+0.49
+64.08%
Financial Health
0
1
2
3
4
5
6
7
8
9

Hoth Therapeutics stock price monthly change

-13.03%
month

Hoth Therapeutics stock price quarterly change

-13.03%
quarter

Hoth Therapeutics stock price yearly change

-51.92%
year

Hoth Therapeutics key metrics

Market Cap
5.62M
Enterprise value
N/A
P/E
-0.23
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
N/A
Price/Book
0.48
PEG ratio
N/A
EPS
-2.02
Revenue
N/A
EBITDA
-7.39M
Income
-7.70M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Hoth Therapeutics stock price history

Hoth Therapeutics stock forecast

Hoth Therapeutics financial statements

Hoth Therapeutics, Inc. (NASDAQ:HOTH): Profit margin
Jun 2023 0 -1.87M
Sep 2023 0 -2.08M
Dec 2023 59.53K -1.70M -2859.13%
Mar 2024 0 -2.04M
Hoth Therapeutics, Inc. (NASDAQ:HOTH): Analyst Estimates
Mar 2024 0 -2.04M
Sep 2025 0 -1.17M
Oct 2025 0 -1.18M
Dec 2025 0 -1.05M
  • Analysts Price target

  • Financials & Ratios estimates

Hoth Therapeutics, Inc. (NASDAQ:HOTH): Earnings per share (EPS)
2023-06-14 -2.29 -2.86
Hoth Therapeutics, Inc. (NASDAQ:HOTH): Debt to assets
Jun 2023 11917250 1.96M 16.5%
Sep 2023 12086137 1.57M 13.06%
Dec 2023 9520278 704.98K 7.41%
Mar 2024 8491329 658.73K 7.76%
Hoth Therapeutics, Inc. (NASDAQ:HOTH): Cash Flow
Jun 2023 -1.44M 0 0
Sep 2023 -1.63M 0 2.40M
Dec 2023 -3.07M -1 0
Mar 2024 -1.72M 0 0

Hoth Therapeutics alternative data

Hoth Therapeutics, Inc. (NASDAQ:HOTH): Employee count
Aug 2023 2
Sep 2023 2
Oct 2023 2
Nov 2023 2
Dec 2023 2
Jan 2024 2
Feb 2024 2
Mar 2024 2
Apr 2024 2
May 2024 2
Jun 2024 2
Jul 2024 2

Hoth Therapeutics other data

4.18% -95.82%
of HOTH is owned by hedge funds
50.01K -119.10K
shares is hold by hedge funds

Hoth Therapeutics, Inc. (NASDAQ:HOTH): Insider trades (number of shares)
Period Buy Sel
Sep 2022 20000 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
KNIE ROBB director, officer.. Common Stock 10,000 $0.39 $3,900
Purchase
KNIE ROBB director, officer.. Common Stock 10,000 $0.4 $4,000
Sale
HAYES ANTHONY 10 percent owner Common Stock, par value $0.0001 400,000 $0.63 $250,000
Sale
AIKIDO PHARMA INC.
Common Stock 400,000 N/A N/A
Sale
HAYES ANTHONY 10 percent owner Common Stock, par value $0.0001 400,000 N/A N/A
Purchase
SPHERIX INC 10 percent owner
Common Stock 35,714 N/A N/A
Purchase
SPHERIX INC 10 percent owner
Common Stock 1,700,000 N/A N/A
Insider Compensation
Mr. Robb Knie (1969) Pres, Chief Executive Officer & Chairman $525,000
Ms. Jane H. Springer (1985) Vice President of Operations
$215,000
Wednesday, 20 November 2024
prnewswire.com
Tuesday, 29 October 2024
prnewswire.com
Tuesday, 15 October 2024
prnewswire.com
Tuesday, 17 September 2024
prnewswire.com
Friday, 6 September 2024
zacks.com
Thursday, 5 September 2024
prnewswire.com
prnewswire.com
Thursday, 15 August 2024
prnewswire.com
Wednesday, 24 July 2024
investorplace.com
Tuesday, 16 July 2024
prnewswire.com
Monday, 10 June 2024
prnewswire.com
Wednesday, 1 May 2024
prnewswire.com
Wednesday, 27 March 2024
prnewswire.com
prnewswire.com
Wednesday, 20 March 2024
Zacks Investment Research
Tuesday, 13 February 2024
PRNewsWire
Tuesday, 6 June 2023
InvestorPlace
Thursday, 23 February 2023
PennyStocks
Friday, 30 December 2022
Benzinga
Monday, 31 October 2022
InvestorPlace
Friday, 12 August 2022
PRNewsWire
Tuesday, 12 July 2022
Benzinga
Benzinga
Sunday, 26 June 2022
PennyStocks
Tuesday, 19 April 2022
Benzinga
Tuesday, 12 April 2022
PRNewsWire
Monday, 11 April 2022
Benzinga
InvestorPlace
Benzinga
Benzinga
  • What's the price of Hoth Therapeutics stock today?

    One share of Hoth Therapeutics stock can currently be purchased for approximately $1.27.

  • When is Hoth Therapeutics's next earnings date?

    Unfortunately, Hoth Therapeutics's (HOTH) next earnings date is currently unknown.

  • Does Hoth Therapeutics pay dividends?

    No, Hoth Therapeutics does not pay dividends.

  • How much money does Hoth Therapeutics make?

    Hoth Therapeutics has a market capitalization of 5.62M. Hoth Therapeutics made a loss 7.85M US dollars in net income (profit) last year or -$2.86 on an earnings per share basis.

  • What is Hoth Therapeutics's stock symbol?

    Hoth Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "HOTH".

  • What is Hoth Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Hoth Therapeutics?

    Shares of Hoth Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Hoth Therapeutics's key executives?

    Hoth Therapeutics's management team includes the following people:

    • Mr. Robb Knie Pres, Chief Executive Officer & Chairman(age: 56, pay: $525,000)
    • Ms. Jane H. Springer Vice President of Operations(age: 40, pay: $215,000)
  • How many employees does Hoth Therapeutics have?

    As Jul 2024, Hoth Therapeutics employs 2 workers.

  • When Hoth Therapeutics went public?

    Hoth Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 15 Feb 2019.

  • What is Hoth Therapeutics's official website?

    The official website for Hoth Therapeutics is hoththerapeutics.com.

  • Where are Hoth Therapeutics's headquarters?

    Hoth Therapeutics is headquartered at 1 Rockefeller Plaza, New York, NY.

  • How can i contact Hoth Therapeutics?

    Hoth Therapeutics's mailing address is 1 Rockefeller Plaza, New York, NY and company can be reached via phone at +64 6 756 2997.

Hoth Therapeutics company profile:

Hoth Therapeutics, Inc.

hoththerapeutics.com
Exchange:

NASDAQ

Full time employees:

2

Industry:

Biotechnology

Sector:

Healthcare

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.

1 Rockefeller Plaza
New York, NY 10020

CIK: 0001711786
ISIN: US44148G2049
CUSIP: 44148G105